HDAC9 and plasma cell myeloma: Though the molecule is approved and registered as a combinational chemotherapeutic to treat multiple myeloma, the mutagenicity and genotoxicity along with the poor pharmacokinetic profile of the drug significantly decreases the viability of the drug for amoebae, but suggests that HDAC might be a target for future studies [50].